Shigellosis is an acute inflammatory disease of the gastrointestinal tract caused by bacteria belonging to the genus *Shigella* and characterized by fever, abdominal cramping pain, and loose stools, which may contain mucus, pus, and blood; however, some patients develop only acute, nonspecific watery diarrhea. Bacillary dysentery can also be caused by other enteric pathogens, especially *Campylobacter*, enteroinvasive *Escherichia coli*, and enterohemorrhagic *E. coli*. However, the only organism causing dysentery that is frequently associated with clinically severe disease that may result in death is *Shigella*. Since visible blood in the stool generally indicates a more severe form of the disease, this symptom has generally been chosen as the marker for recognition of clinically important bacillary dysentery.

Shigellosis has a global distribution; because the infection is transmitted by the fecal-oral route, the prevalence of the disease is highest in countries where hygiene and sanitation are poor. As few as 10–100 viable *Shigella* can cause the disease in adult volunteers; this probably explains why person-to-person transmission is the most common mode of spread of this disease.

**Morbidity and Mortality Due to Shigellosis**

During the last 20 years, endemic shigellosis (most often due to *Shigella flexneri* or *Shigella boydii*) and epidemic shigellosis (most often due to *Shigella dysenteriae* type 1) have been recognized as important causes of morbidity and death in children <5 years of age in many developing countries. In Bangladesh, a survey of patients hospitalized at the International Center for Diarrheal Diseases Research (ICDDR,B) in Dhaka over a 14-year period showed that 21% of all patients with bacillary dysentery due to *Shigella* were <1 year old and that 44% were from 1 to 4 years old [1]. A community-based survey carried out in a rural area of Bangladesh showed that 30% of cases of culture-proven shigellosis occurred in children <5 years old and 54% in children <10 years old [2].

No data concerning mortality rates due to dysen-
tery are available from community-based studies. However, before the widespread implementation of oral rehydration therapy (ORT) for watery dehydrating diarrhea, it was estimated that shigellosis accounted for 15% of diarrheal deaths. As the use of ORT increases and deaths due to acute dehydration decline, this percentage would inevitably rise.

In patients hospitalized for shigellosis, reported mortality rates are between 1% and 10%, depending on the epidemiologic situation [3, 4]. During the 1972–1978 epidemic due to S. dysenteriae type 1, the case-fatality rate at the well-equipped hospital of the ICDDR,B was ~10%; in contrast, the case-fatality rate for cholera in the same hospital was ~0.5% during the same period.

Shigellosis is more frequently severe in young children, as shown by the case-fatality rates observed in 4 years (1969, 1974, 1980, and 1982) at the ICDDR,B hospital (table 1). In fact, 87% of the deaths in patients admitted to the hospital with shigellosis occurred in children <5 years of age, and 96% in children <10 years of age [1].

Risk factors that characterize children at highest risk of death from dysentery have been identified in several studies [4, 5]. These factors are summarized as follows: (1) malnutrition—severely malnourished children (i.e., those for whom the ratio of weight for age is <60% of the median of the standards of the National Center for Health Statistics) have a three- to sevenfold increased risk of dying, compared with better nourished children; (2) age—children with shigellosis who are <1 year old have a threefold increased risk of dying compared with children who are >1 year old; (3) children who have not been breast-fed; (4) moderate or severe dehydration at presentation; (5) absence of fever at presentation; (6) presence of bacteremia; and (7) persistent diarrhea (i.e., an episode of diarrhea lasting for >2 weeks).

It has been shown that among all diarrheal episodes of known etiology, shigellosis has the greatest negative impact on linear growth [6]. It was found that diarrheal episodes due to Shigella lasted longer than other types of diarrhea and caused greater losses of serum protein. Moreover, the problem of protein loss is exacerbated by poor dietary intake as a result of prolonged anorexia.

From the preceding, it is apparent that prevention or effective treatment of shigellosis would not only diminish mortality due to diarrhea but should also have a significant positive impact on growth and nutritional status.

**Antibiotic Resistance**

When combined with appropriate dietary management, ORT, which can prevent or treat clinically evident dehydration, is the basis for effective treatment of acute watery diarrhea. In shigellosis, however, antibiotics are required. When appropriately used, antibiotics have been shown to substantially reduce the severity of the illness and to shorten its duration [8, 9].

Some of the antibacterial agents that have been used to treat shigellosis are tetracycline (single or multiple doses), ampicillin (single or multiple doses), trimethoprim-sulfamethoxazole (TMP-SMZ; multiple doses for 5 days), nalidixic acid (multiple dose for 5 days), trimethoprim alone (multiple doses for 5 days), chloramphenicol, and ceftriaxone (intravenous).

The effectiveness of these agents has, however, been seriously impaired by the widespread emergence of bacterial resistance—often to multiple antibiotics—especially in S. dysenteriae type 1. Tetracyclines were the first widely used effective antibiotics administered in a single dose (2.5 g) or multiple doses over a 3- to 5-day period [10]. When Shigella developed resistance to tetracyclines, ampicillin became the drug of choice; however, in the early 1980s ampicillin-resistant strains appeared and became widespread in Asia [11] and Africa [12]. TMP-SMZ then became the drug of choice. However, shortly after it assumed this role, resistance appeared; for example, in 1980 100% of Shigella strains isolated in Dhaka, Bangladesh, were sensitive to TMP-SMZ, whereas 4 years later only 45% were sensitive [11].

These changing patterns of sensitivity were well illustrated during a recent epidemic of S. dysenteriae type 1 in Central Africa. At the beginning of the epidemic in 1980, the first isolates were already resis-

---

**Table 1. Case-fatality rate for children hospitalized with shigellosis.**

<table>
<thead>
<tr>
<th>Age group</th>
<th>Case-fatality rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 y</td>
<td>13.8</td>
</tr>
<tr>
<td>1-4 y</td>
<td>8.3</td>
</tr>
<tr>
<td>5-9 y</td>
<td>5.1</td>
</tr>
<tr>
<td>≥10 y</td>
<td>0.1</td>
</tr>
</tbody>
</table>

**NOTE.** Data are from [1].
tant to ampicillin, tetracyclines, chloramphenicol, and sulfonamides; therefore, TMP-SMZ was widely used as therapy. By 1982, resistance to TMP-SMZ had become a major problem, occurring almost equally in both epidemic and endemic strains.

The emergence of strains resistant to the three major antimicrobial agents (tetracycline, ampicillin, and TMP-SMZ) led to the use of nalidixic acid, although evidence of its efficacy, based on results of controlled studies, was scanty. Indeed, a study performed in 1973 [13] had shown that although nalidixic acid was effective in vitro against most strains of *Shigella*, stool cultures remained positive longer in patients who received nalidixic acid than in those who received ampicillin, and the clinical response was slower. In fact, the authors concluded that "nalidixic acid had little effect on the course of the disease." Nevertheless, nalidixic acid is now being used for the initial treatment of shigellosis in many countries where strains resistant to other antibiotics are commonly encountered (e.g., Bangladesh, India, Rwanda).

The need for more effective antimicrobial agents for the treatment of shigellosis is evident. The Diarrhoeal Diseases Control (CDD) Programme of the World Health Organization has therefore made one of its research priorities the identification of alternative antibiotics for use in the treatment of shigellosis in young children in areas where severe illness due to strains resistant to ampicillin and TMP-SMZ occurs. Some of the drugs now under consideration are as follows:

1. **Oral gentamicin.** Nearly all *Shigella* strains are sensitive to gentamicin in vitro; however, this drug is not absorbed from the gastrointestinal tract, and it is not likely that therapeutic concentrations of the drug are attained in the bowel wall. In China, oral gentamicin is considered effective and widely used; however, there are no controlled studies that establish its efficacy.

2. **Pivmecillinam.** This penicillin analogue, given orally, has been shown to be effective for the treatment of adults with shigellosis in Bangladesh [14].

3. **Bicozamycin.** This is a nonabsorbable antibiotic with a wide spectrum of activity against gram-negative enteric organisms and no relationship to other widely used antibiotics. Despite its being nonabsorbable, bicozamycin was shown to be effective in treating diarrhea due to *Shigella* in adult travelers [15]. However, bicozamycin is not marketed at present.

4. **Doxycycline.** A single study has shown that adults infected with tetracycline-resistant *Shigella* (resistant to 12.5 mg/L) responded adequately to treatment with a single large oral dose (2.5 g) of tetracycline [10]. The possibility that doxycycline, a long-acting tetracycline, given in a single dose may be effective even for antibiotic-resistant strains should be explored.

5. **Fluoroquinolones.**

The new quinolone antibiotics (fluoroquinolones) are closely related to nalidixic acid and have been shown to be highly effective in vitro against *Shigella*. The MIC<sub>50</sub> and MIC<sub>90</sub> of nalidixic acid and of five fluoroquinolones for *Shigella* are compared in table 2 [16]. This table shows that the new quinolones are highly active in vitro against *Shigella*. Norfloxacin and ciprofloxacin seem to be less completely absorbed from the gastrointestinal tract than are the other fluoroquinolones; these two antibiotics have also been reported to achieve a high concentration in stools (773 mg/L for norfloxacin and 891 mg/L for ciprofloxacin) [17]. In addition, 48 hours after a single 400-mg oral dose of norfloxacin, a high level of the antibiotic (>40 μg/g) remains in the feces [18].

For these reasons, norfloxacin and ciprofloxacin appear to be promising agents for use in the treatment of shigellosis. The high concentration of the drug still present in the feces 48 hours after a single 400-mg oral dose leads us to consider that single-dose therapy (or perhaps a daily dose given for 2 days) might be effective for the treatment of shigellosis. A simple treatment regimen of this type would be advantageous for the provision of effective therapy under conditions where the reliable delivery of medication for a longer period is very difficult.

Clinical studies with oral fluoroquinolones mostly

### Table 2. In vitro activity against *Shigella* of 5-fluoroquinolones and nalidixic acid.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration (mg/L)</th>
<th>MIC&lt;sub&gt;50&lt;/sub&gt;</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nalidixic acid</td>
<td></td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>0.03</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0.02</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>0.1</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>Enoxacin</td>
<td>0.1</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Pefloxacin</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
</tbody>
</table>
concern the use of these drugs in infections of the genitourinary tract. One published study, however, compared the efficacy of norfloxacin vs. nalidixic acid in the treatment of adults with shigellosis during an epidemic in Rwanda due to S. dysenteriae type 1 [19]. The results of this study suggest that norfloxacin is superior to nalidixic acid with respect to clinical response and elimination of Shigella from the stools. However, because of the limited number of patients treated in this study and because it was not controlled, no definite conclusions could be drawn. Other studies of adults have shown that Shigella was eradicated within 48 hours after the administration of norfloxacin and that the clinical response in patients receiving norfloxacin was similar to that observed in patients receiving TMP-SMZ [18, 20].

As mentioned above, the new quinolones are closely related to nalidixic acid and therefore also share the toxicities of that drug, including effects on the CNS (lightheadedness, headache, drowsiness, and insomnia); cutaneous reactions (skin rash and pruritus, phototoxic reactions ranging from mild erythema in areas exposed to the sun to extensive bullous eruptions that mimic porphyria [21]); and rheumatologic symptoms (swelling and stiffness of the joints, arthralgia, myalgia [17, 21]).

However, the number of adverse effects reported to date among patients treated with fluoroquinolones appears to be low (5%-25%); therapy has been discontinued as a result of development of adverse reactions in only 1%-3% of patients [21].

Toxicity to cartilage, known to be a characteristic of nalidixic acid, has also been reported in animals treated with fluoroquinolones. This toxicity includes inhibition of the growth of juvenile cartilage; inhibition of the growth of cartilaginous limb buds in embryonic mice; and erosions of the articular cartilage, with hypertrophy and eosinophilia of the chondrocytes, in dogs given high doses of nalidixic, oxolinic, or pipemidic acids (200-350 mg/kg) [22-24].

The relationship of these experimental results to the rheumatologic symptoms observed in patients treated with nalidixic acid is still uncertain. Indeed, nalidixic acid has been used for years for the treatment of childhood infections without any report of secondary arthropathy [25, 26]. Arthropathies have been reported in patients being treated with the newer quinolones [17], but these patients were all receiving long-term therapy for chronic infection. The adverse effects, including the rheumatologic symptoms, observed with the newer quinolones all regressed when therapy was discontinued, without any need for additional specific treatment.

However, because the toxic effect on bone and cartilage of the newer quinolones is an important concern, fluoroquinolones have not yet been recommended for routine use in pregnant women and in children <15 years of age, whose skeletal growth is incomplete.

Consideration of the Use of Fluoroquinolones to Treat Shigellosis in Young Children

Concern about the safety of fluoroquinolones has until now prevented the evaluation of these drugs for the treatment of shigellosis in young children. However, a review of available information on the safety and efficacy of these agents by the Scientific Working Group on Case Management of the WHO/CDD Programme suggests that this view may be overly cautious for the following reasons:

(1) There is an evident and urgent need for new effective antimicrobial agents for the treatment of shigellosis in young children as a result of the widespread occurrence of strains resistant to available agents.

(2) The new fluoroquinolones have been shown to be active in vitro against Shigella (and Campylobacter species, another important cause of dysentery in young children), and limited evidence suggests that they are also effective in vivo.

(3) Nalidixic acid, which shares all the cartilage toxicity of the fluoroquinolones, is licensed for use in children and is widely recommended for the treatment of shigellosis in young children without any report of major adverse effects [28].

(4) The occurrence of the rheumatologic symptoms associated with the fluoroquinolones seems to be related to the amount of drug absorbed and the duration of treatment. Because of the high concentration of the drug achieved in the feces after even one dose, the amount to be given in a single dose or even a 2-day treatment would be far below that which causes toxic signs in experimental animals. However, a careful monitoring of any adverse effect during the treatment and in the months following should be performed when using the newer quinolones in children, especially in children whose calcium metabolism or growth may be impaired by serious malnutrition.

(5) A risk-benefit analysis of the use of fluoroquinolones in children <15 years of age suggests that
the risks associated with fluoroquinolone treatment
in this age group are far outweighed by the benefits
that effective treatment of this life-threatening dis-
ease could provide [29].

Conclusion
It is likely that the fluoroquinolones could play an
important role in the reduction of the morbidity and
mortality due to shigellosis in young children infected
with strains that are resistant to conventional anti-
biotics. Because the drug would probably be ad-
ministered either as a one-dose treatment, or at most
for 2 days, the amount given would be far below that
which causes toxic signs in animals. Although this
reasoning does not constitute a recommendation for
the routine use of fluoroquinolones for the treatment
which causes toxic signs in animals. Although this
mortality due to shigellosis in young children infected
biotics. Because the drug would probably be ad-
cluded that the information derived from such stud-
ies would contribute substantially to efforts to de-
velop better tools for the control of this important
cause of morbidity and mortality in children.

References
of shigellosis in Dhaka: an epidemiological analysis. Int J
Epidemiol 1985;14:607–13
2. Boyce JM, Hughes JM, Ali MA, Khan M, Aziz KMA.
Wells JG, Cullen GT. Patterns of Shigella infection in fam-
31:1015–20
3. Huppertz HJ. An epidemic of bacillary dysentery in western
4. Duncan B, Fulginiti VA, Sieber OF Jr, Ryan KJ. Shigella sep-
5. Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler
T. Shigella septicemia: prevalence, presentation, risk fac-
with specific enteropathogens on the growth of children
Longitudinal studies of infectious diseases and physical growth
of children in rural Bangladesh. II. Incidence of diarrhea
and association with known pathogens. Am J Epidemiol
1982;115:315–24
8. Haltalin KC, Nelson JD, Ring RR, Sladoje M, Hinton LV.
Double-blind treatment study of shigellosis comparing am-
9. Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treat-
ment of acute diarrhea in outpatients: double-blind study
comparing ampicillin and placebo. Am J Dis Child
1972;124:554–61
therapy for shigellosis in adults. JAMA 1978;239:853–4
11. Murray BE. Resistance of Shigella, Salmonella, and other
selected enteric pathogens to antimicrobial agents. Rev Infect
Dis 1986;8(Suppl 2):S172–81
12. Frost JA, Rowe B, Vandenputte J, Thriftall DE. Plasmid charac-
terisation in the investigation of an epidemic caused by
multiply resistant Shigella dysenteriae, type 1 in Central
13. Haltalin KC, Nelson JD, Kusmiesz HT. Comparative effi-
cacy of nalidixic acid and ampicillin for severe shigellosis.
Arch Dis Child 1973;48:305–12
Comparative efficacies of pimxicillinam and ampicillin
25:643–5
15. Ericson HD, Dupont HL, Galindo E, Mathewson JJ, Mor-
gan DR, Wood LV, Mendiola J. Efficacy of bicozymeine
in preventing traveller’s diarrhea. Gastroenterology
1985;88:473–7
16. Wolfson JS, Hooper DS. The fluoroquinolones: structures,
mechanisms of action and resistance, and spectra of ac
17. Hooper DC, Wolfson JS. The fluoroquinolones: pharmaco-
ology, clinical uses, and toxicities in humans. Antimicrob
Agents Chemother 1985;28:716–21
18. Ruiz-Palacios GM. Norfloxacin in the treatment of bacterial
Habijaremmy I. Comparison of norfloxacin and nalidixic
acid for treatment of dysentery caused by Shigella dysen-
teriae type 1 in adults. Antimicrob Agents Chemother
1986;29:883–6
20. Lolekha S. Consequences of treatment of gastrointestinal in-
21. Smith CR. The adverse effects of fluoroquinolones. J An-
timicrob Chemother 1987;19:709–11
22. Ingham B, Bremnam DW, Dale EA, MacAdzean JA. Ar-
thropathy induced by antibacterial fused N-alkyl-4-
23. Tatsumi H, Senda H, Yatera S, Takemoto Y, Yamayoshi M,
Ohnishi K. Toxicological studies on pipemidic acid. V. Ef-
ect of diarthrodial joints of experimental animals. J Tox-
24. Stahlmann R, Blackenberg G, Neubert D. Studies on cartil-
age formation and differentiation in limb bud culture in
the presence of nalidixic acid, ofloxacin and ciprofloxacin
[abstract no. 147]. In: Program of the International
Symposium on New Quinolones, Geneva, 1986
25. Schaad UB, Wedgewood-Krucko J. Nalidixic acid in children:
retrospective matched controlled study for cartilage tox-
26. Salam MA, Bennish ML. Therapy for shigellosis. A ran-
donized double-blind trial of nalidixic acid in childhood
27. Alfaresh M, Holt ME, Goodchild MC. Arthropathy in pa-
tients with cystic fibrosis taking ciprofloxacin. Br Med J
1987;295:699